Boehringer Ingelheim to Study Afatinib in Patients with Difficult-to-Treat HER2-Positive Breast Cancer

Sep 07, 2011

Premium

Continuing to expand the development program for its irreversible inhibitor of EGFR and HER2, afatinib, Boehringer Ingelheim Pharmaceuticals has launched two new Phase II studies — one investigating the drug as a treatment for inflammatory breast cancer and another for metastatic HER2-positive breast cancer patients who have progressed despite treatment with other HER2-targeted drugs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Whirlwind Genetic Genealogy Year

Wired reports on how genetic genealogy's use in forensics has exploded in the year since an arrest in the Golden State Killer case was made.

Getting Through the Backlog

Retraction Watch reports that the increase in retracted papers at a journal is due to more resources there to tackle publication ethics.

Settlement After DNA Testing Questions

New York City has settled with a forensic scientist who was fired after questioning a DNA testing approach used by the medical examiner's office, the New York Times reports.

This Week in Nature

In Nature this week: technique for measuring replication fork movement, WINTHER trial results, and more.

Featured White Papers

BlueBee Data Security & Compliance

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

Apr

30

Featured Webinar

Novel Methods for Improving De Novo Transcriptome Annotation with Long-Read Transcript Sequencing

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

May

08

Featured Webinar

OncoBEAM ctDNA Testing for Early Response Prediction and Therapy Surveillance in Melanoma and Pancreatic Cancer

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.

May

15

Featured Webinar

Discovery of Exon-Level CNVs in Daily Practice for Constitutional Genome Testing

This webinar will discuss how Radboud University Medical Center’s Department of Human Genetics is using exon-level copy number variant (CNV) detection by microarray to assist its efforts in constitutional genome testing.

May

16

Featured Webinar

A Comprehensive Workflow for Soil Metagenomics Analysis Using Shotgun Sequencing

This webinar will discuss a comprehensive end-to-end workflow for soil metagenomic shotgun sequencing that offers an unbiased alternative to amplicon-based approaches to assess the composition of culture-free microbial communities and predict functional profiles.

Menu